SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to a report of security flaws in a battlefield communications system, leading to a sharp intraday drop. While some investors are concerned about the implications of these vulnerabilities, others view the dip as a buying opportunity, citing the company's response that the issues have been addressed and the prototype nature of the system.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a mix of excitement and skepticism around its recent surge, with community members debating whether it's a legitimate rise or a potential bubble. The stock's connection to the quantum computing sector and AI, coupled with discussions about its valuation and revenue, are fueling the conversations. Some traders are pointing to potential short squeezes, while others are wary of a significant pullback.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amid high trading volume and community excitement, with some investors anticipating significant catalysts in the near future, possibly driven by speculation around new partnerships. Community members are pointing to the high short interest, hinting at a potential squeeze, while also highlighting the company's potential for growth in the eVTOL sector.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

LKNCY is trending as investors celebrate the stock finally breaking the $40 mark, a level many have been watching for a long time, driven by expansion news. The community is expressing bullish sentiment, anticipating further growth and a potential Nasdaq relisting. Overall, the mood is optimistic as traders reflect on the company's journey and future potential.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors debate the implications of its AI spending and recent moves into private debt markets, drawing comparisons to pre-2008 financial tactics. Community discussion revolves around the stock's volatility and whether its pullback represents a buying opportunity or reflects deeper concerns about AI investments. Some are pointing to potential data center deals as a possible catalyst.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience ($ANRO) is trending as investors react to news of $IMG pulling its S-1 filing, eliminating concerns about potential dilution. The community is also buzzing about ANRO's expansion into crypto AI, including a $55M Bitcoin deal and a $20M fund with iZUMi. Bullish sentiment seems to be building amidst discussions of potential breakouts and short squeezes.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its vision, encapsulated by the phrase "Like Bitcoin But Way Higher". Active discussions involve the project's roadmap and potential, with community members emphasizing its cultural relevance and potential for growth, particularly regarding developments in the broader cannabis industry.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble ($RUM) is trending due to its strategic partnership with Perplexity AI, sparking discussions about enhanced content discovery and potential synergies within the AI space. The community is actively debating the impact of this partnership, especially given Rumble's existing ties to crypto through Tether and its potential to become a major cloud provider. High short interest is adding fuel to the fire, with many anticipating a significant short squeeze.

Richtech Robotics, Inc. engages in the development of robotic technologies. The firm designs, manufactures, and sells robots to restaurants, hotels, senior living centers, casinos, factories, and movie theaters. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company was founded by Zhen Wu Huang and Zhen Qiang Huang on July 19, 2016 and is headquartered in Las Vegas, NV.

Richtech Robotics Inc. - Ordinary Shares - Class B

Richtech Robotics Inc.

Richtech Robotics ($RR) is trending with significant volume, fueled by community excitement and talk of a potential surge to new highs. Investors are actively discussing the company's potential to reach mid-cap status and the anticipation of news in October, while some reference a past short report as a catalyst for the stock's recent momentum. Discussion also includes comparisons to other robotics companies and speculation around the impact of robotics on the future.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending as the stock experiences a significant sell-off, sparking debates among investors about potential causes, including a Bloomberg article referencing a competitor's GLP-1 product offering. The community is actively discussing whether the sell-off is an overreaction and if the company's fundamentals remain strong, while also eyeing potential bounce-back opportunities. Some traders speculate about algo manipulation and stop-loss triggers amidst the volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz

Shares of Inozyme Pharma, Inc. (INZY) rocketed 179% on Friday after BioMarin Pharmaceutical (BMRN) agreed to <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.inozyme.com/news-releases/news-release-details/biomarin-strengthens-enzyme-therapy-business-acquisition-inozyme">acquire</a> the company for $270 million.Under the deal, BioMarin will acquire Inozyme for $4 per share in an all-cash transaction. The deal's per-share price consideration implies an 182% premium to Inozyme’s closing price of $1.42 on Thursday.BioMarin will commence a cash tender to acquire all of Inozyme's outstanding shares. A majority of the outstanding shares must be tendered for its consummation.Inozyme's Board of Directors unanimously recommended that shareholders tender their shares in the offer.Following the successful completion of the tender offer, a wholly-owned subsidiary of BioMarin will merge with Inozyme. The transaction is expected to close in the third quarter of 2025.BioMarin said that it expects the acquisition to strengthen its enzyme therapies portfolio.Inozyme’s late-stage enzyme replacement therapy, INZ-701, is currently being assessed for the treatment of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 deficiency (ENPP1), a rare genetic disorder caused by mutations in the ENPP1 gene, leading to loss of ENPP1 enzymatic activity. Currently, there are no approved therapies for ENPP1 Deficiency, Inozyme said.BioMarin CEO Alexander Hardy said that the company will continue to evaluate both external and internal innovation going forward.“We are in a strong financial position to bring in additional assets as we accelerate the development of medicines for patients with significant unmet need," he said.On Stocktwits, retail sentiment around Inozyme jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume jumped from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_16_at_12_31_33_PM_png_8f9ddbb20d.webp" alt="INZY's Sentiment Meter and Message Volume as of 12:30 p.m. ET on May 16, 2025 | Source: Stocktwits" width="628" height="60"><figcaption>INZY's Sentiment Meter and Message Volume as of 12:30 p.m. ET on May 16, 2025 | Source: Stocktwits</figcaption></figure>For BioMarin, retail sentiment around the company fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours.<figure class="image"><img style="aspect-ratio:626/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_16_at_12_32_33_PM_png_3cde3c49bc.webp" alt="BMRN's Sentiment Meter and Message Volume as of 12:30 p.m. ET on May 16, 2025 | Source: Stocktwits" width="626" height="64"><figcaption>BMRN's Sentiment Meter and Message Volume as of 12:30 p.m. ET on May 16, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/INZY">INZY stock</a> has gained by 39% this year but has fallen by nearly 16% over the past 12 months.<a href="https://stocktwits.com/symbol/BMRN">BMRN stock</a> is trading nearly 2% higher as of Friday noon.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/volkswagen-shareholders-flag-governance-issues-at-car-company/chiwBRDRbnU">Volkswagen Shareholders Flag Governance Issues At Carmaker, Says Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens

The deal's per-share price consideration implies an 182% premium to Inozyme’s closing price of $1.42 on Thursday.

Inozyme Stock Rockets 178% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens

Equity

The deal's per-share price consideration implies an 182% premium to Inozyme’s closing price of $1.42 on Thursday.


Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'

Stifel initiates coverage on Inozyme Pharma with a Buy rating and a $16 price target, highlighting INZ-701's potential to treat rare diseases like ENPP1 and ABCC6 deficiencies.
read more...

Inozyme Pharma, Inc. (NASDAQ:INZY) CEO Douglas A. Treco Sells 7,523 Shares

Inozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) CEO Douglas A. Treco sold 7,523 shares of the business's stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an...

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) ( Company or Inozyme ), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...

Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) ( the Company or Inozyme ), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics...

Inozyme Pharma (INZY, $7.3) RSI Indicator left the overbought zone on April 01, 2024

This is a signal that INZY's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Inozyme Pharma (INZY, $7.4) RSI Indicator left the overbought zone on March 27, 2024

Inozyme Pharma (INZY, $6.78) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 26, 2024

This is a Bullish indicator signaling INZY's price could rise from here. Traders may explore going long the stock or buying call options...

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. It engages in the business of developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.

Inozyme Pharma Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

INZY
Inozyme Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest INZY News

INZY Inozyme Pharma Inc